Zobrazeno 1 - 10 of 12 pro vyhledávání: '"Sarper Toker"'
1
Akademický článek
A Narrative Review of the Clinical, Humanistic, and Economic Value of Pembrolizumab-Based Immunotherapy for the Treatment of Breast and Gynecologic Cancers
Autor: Matthew J. Monberg, Steve Keefe, Vassiliki Karantza, Konstantinos Tryfonidis, Sarper Toker, Jaime Mejia, Robert Orlowski, Amin Haiderali, Vimalanand S. Prabhu, Gursel Aktan
Publikováno v: Oncology and Therapy, Vol 12, Iss 4, Pp 701-734 (2024)
Abstract Breast and gynecologic cancers are common across the world and are associated with substantial societal and economic burden. Pembrolizumab was among the first immune checkpoint inhibitors targeting programmed cell death protein 1 to be appro
Externí odkaz: https://doaj.org/article/630b445260414282bc5b37dc22adf808
Zobrazit plný text záznamu
2
Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer
Autor: Eduardo Yañez, Nicoletta Colombo, Kan Li, Vanessa Samouëlian, Alexander Arkhipov, Pamela Salman, Stephen Michael Keefe, Mahmut Gumus, M Valeria Caceres, Sarper Toker, Mivael Olivera Hurtado de Mendoza, Bradley J. Monk, Edwin Hoyos Usta, Domenica Lorusso, Vincent Castonguay, Ronnie Shapira-Frommer, Keynote Investigators, Krishnansu S. Tewari, Kosei Hasegawa, Coraline Dubot
Publikováno v: The New England journal of medicine. 385(20)
Pembrolizumab has efficacy in programmed death ligand 1 (PD-L1)-positive metastatic or unresectable cervical cancer that has progressed during chemotherapy. We assessed the relative benefit of adding pembrolizumab to chemotherapy with or without beva
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::93f227df3820e07ca3d25089fcefb630
https://pubmed.ncbi.nlm.nih.gov/34616034
Zobrazit plný text záznamu
5
Abstract 5783: Strong antitumor activity of ASN007, an oral ERK1/2 inhibitor, in PDX tumor models with MAP kinase pathway alterations including KRAS mutations
Autor: Sarper Toker, Scott K. Thompson, Niranjan Rao, Sanjeeva P. Reddy, Roger Smith
Publikováno v: Cancer Research. 78:5783-5783
The RAS/RAF/MEK pathway is frequently dysregulated in a broad range of cancers through mutations in several targets such as KRAS, NRAS, HRAS, BRAF, NF1 and receptor tyrosine kinases. Although MEK and BRAF inhibitors improve the outcome for patients w
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9f1666201e88b7bcbce611dee880cd1a
https://doi.org/10.1158/1538-7445.am2018-5783
Zobrazit plný text záznamu
6
Abstract CT019: ASN003, a novel highly selective BRAF and PI3K dual inhibitor: Phase I PK/PD results in patients with advanced solid tumors
Autor: Sanjeeva P. Reddy, Sarper Toker, Monica M. Mita, Anthony W. Tolcher, Drew W. Rasco, Helen Usansky, Ryan J. Sullivan, Keith T. Flaherty, Louis Denis, Jaimini Shah, Nehal Lakhani, Niranjan Rao
Publikováno v: Cancer Research. 78:CT019-CT019
Background RAS-RAF-MEK and PI3K-AKT-mTOR are two major pathways involved in tumor cell signaling and growth. Components of these pathways are frequently mutated in a broad range of tumors. ASN003 is a highly selective and potent (low nM IC50) inhibit
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c6280fe0cb6f7646a9fe462ece1b6aee
https://doi.org/10.1158/1538-7445.am2018-ct019
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje